Asian Paints Q4 profit In-Line with estimates
Asian Paints has announced the following Q4 & FY16 results for the quarter & year ended March 31, 2016:
Standalone (Audited)
For the Quarter ended March 31, 2016 (YoY)
The Company has posted a net profit of Rs386.95 crore Vs Rs339.82 crore.
Total Income increased to Rs3262.67 crore Vs Rs2936.36 crore.
Cadila Healthcare gets USFDA approval for Glyburide tablets
Pharma major, Cadila Healthcare Ltd said that it has received final approval from the USFDA to market Glyburide Tablets USP in strengths of 1.25, 2.5 and 5 mg.
Glyburide, which is an anti-diabetic drug will be produced at the group’s formulations manufacturing facility at Baddi, the company said in a filing to the Bombay Stock Exchange.
Kotak Mahindra Bank Q4 consolidated net profit at Rs1055 cr
Kotak Mahindra Bank has announced the following Q4 & FY16 results for the quarter & year ended March 31, 2016
Standalone
For the Quarter ended March 31, 2016 (Audited)
The Bank has posted a net profit of Rs695.78 crore Vs Rs527.14 crore (YoY).
Total Income is Rs4947.32 crore Vs Rs3249.08 crore (YoY).
Havells Q4FY16 Result update: Largely in-line with street estimates
Havells Q4: Net Profit at Rs.366.5 Cr Vs Rs.122 Cr (YoY)
Total Income +9.3% at Rs.1, 475 Cr Vs Rs.1, 349 Cr (YoY)
Exceptional Gain at Rs.202.4 Cr
EBITDA +21.5% at Rs.220 Cr Vs Rs.181 Cr (YoY)
EBITDA Margin At 14.8% Vs 13.4% (YoY)
Havells Q4FY16 Result update: Largely in-line with street estimates.
Vakrangee Q4: Cons Net Profit at Rs110.8 cr
Vakrangee Q4: Cons Net Profit at Rs.110.8 Cr Vs Rs.102.8 Cr (QoQ)
Total Income at Rs.880 Cr Vs Rs.819 Cr (QoQ)
Read our more services below:
CapitalStars Financial Research Financial Advisory Services
No comments:
Post a Comment